Last edition
News about "Amyotrophic Lateral Sclerosis (ALS)"
Coya Therapeutics Wins FDA Fast Track for COYA 302 in Amyotrophic Lateral Sclerosis
Coya Therapeutics receives US Food and Drug Administration (FDA) Fast Track designation for COYA 302, an investigational biologic therapy for Amyotrophic Lateral Sclerosis (ALS).
Amyotrophic Lateral Sclerosis (ALS) | 13/05/2026 | By News Bureau
Shionogi to Acquire Global Rights to RADICAVA ORS and IV RADICAVA
Shionogi plans to acquire the global rights and assets of Tanabe Pharma's RADICAVA ORS (edaravone) and IV RADICAVA, strengthening its rare disease portfolio, establishing a dedicated commercial platform in the U.S., and adding an estimated USD 700 million in annual global sales, with the transaction expected to be immediately accretive in FY26.
Amyotrophic Lateral Sclerosis (ALS) | 26/12/2025 | By News Bureau | 172
NMPA Clears Zhimeng Biopharma's Drug for Phase-II Epilepsy Trial
Zhimeng Biopharma’s drug for Phase II epilepsy trial will be evaluated in a randomized, double-blind, placebo-controlled multinational study to test its efficacy, safety, and tolerability as an adjunct therapy in adults with focal epilepsy.
Amyotrophic Lateral Sclerosis (ALS) | 13/09/2025 | By Dineshwori | 203
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy